DDW 2026: Key Readouts From the Conference

Why It Matters

These data could expand market share for established biologics, introduce new acid‑blocker competition, and accelerate adoption of novel radiation and robotic endoscopy technologies, reshaping GI therapeutic and diagnostic landscapes.

Key Takeaways

• Skyrizi cut steroid use to 7% after one year in Crohn’s
• Tremfya achieved 28.3% fistula remission, first in class
• Tegoprazan healed 69.4% of erosive esophagitis patients at week 24
• Alpha DaRT delivered 100% local control in early pancreatic cancer trials

Pulse Analysis

The IBD arena received a boost at DDW 2026 as AbbVie’s real‑world Skyrizi data demonstrated a dramatic reduction in corticosteroid dependence, a key safety metric for chronic Crohn’s management. Meanwhile, Johnson & Johnson’s Tremfya became the first IL‑23 inhibitor to show meaningful perianal fistula closure, a notoriously hard‑to‑treat manifestation affecting up to a third of Crohn’s patients. These outcomes reinforce the premium placed on long‑term steroid‑sparing efficacy and could drive formulary shifts toward agents that deliver both symptom relief and quality‑of‑life gains.

Beyond inflammation, the conference highlighted emerging competition in the esophageal space. Dupixent’s 9% improvement in esophageal distensibility marks a significant advance for eosinophilic esophagitis, a niche yet growing market where only two therapies are currently approved. Simultaneously, Sebela’s potassium‑competitive acid blocker tegoprazan outperformed the PPI lansoprazole, achieving 69.4% sustained healing at 24 weeks. With vonprazan (Voquezna) already on the market, tegoprazan’s comparable efficacy and safety profile suggest a multi‑player post‑PPI landscape capable of supporting robust pricing power for new entrants.

Innovation extended to oncology and diagnostics. Alpha Tau’s Alpha DaRT radiotherapy delivered 100% local disease control in early pancreatic cancer trials, hinting at a potential role as a localized adjunct to chemotherapy rather than a systemic replacement. In parallel, Neptune Medical’s Triton robotic colonoscopy achieved flawless caecal intubation and high polyp detection rates, positioning the platform as a tool for improving procedural ergonomics and consistency. While larger comparative studies are needed, these technologies could reshape standards of care, prompting investment in AI integration, training programs, and reimbursement pathways.